http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
방승민 ( Seungmin Bang ) 대한췌담도학회 2016 대한췌담도학회지 Vol.21 No.4
췌장암은 비약적인 현대 의학의 발전에도 불구하고 5년 생존율이 여전히 5% 미만인 인류 최악의 악성 종양이다. 특히효과적인 조기 진단검사와 백신을 이용한 일차 예방을 통해위암, 대장암 및 간암의 생존율이 눈부시게 향상되고 있음에 비해 췌장암은 여전히 조기 진단을 위한 생물학적 표지자나 영상학적 검사가 없는 실정이다. 이러한 임상적 한계는 췌장암의 80% 이상이 근치적 절제수술이 어려운 진행성 상태로 진단되어 그 예후를 더욱 불량하게 만들고 있다. 또한 췌장암은 발생 초기부터 전신 질환으로의 특성을 보이는 것으로 간주되고 있다. 이는 근치적 수술이 가능한 췌장암의 경우 수술후 간을 포함한 전이가 매우 빈번하다는 점과 췌장암 발생 초기에 이미 전신 전이가 진행된다는 실험적 연구 결과들을 통해 추정 가능하다. 즉, 대부분의 췌장암 환자는 전신 항암 치료가 필요함에도 불구하고 1990년대부터 표준적 전신 항암치료제로 사용되고 있는 gemcitabine이 여전히 표준 치료제라는 사실은 췌장암의 치료가 얼마나 어려운지를 시사하는 바가 크다 하겠다. 최근 FOLFIRINOX 및 albumin bounded paclitaxel/gemcitabine 병용요법이 전신상태가 상대적으로 양호한 진행성 췌장암 환자에서 괄목할 만한 효과를 보이고있어, 진행성 췌장암의 치료에 새로운 희망을 불러오고 있다. 이와 더불어 immune check point inhibitor, CAR-T cell 등을 기반으로 하는 면역 치료, 암세포 특이 표적을 이용한 새로운 표적 치료제 및 췌장암 조직의 특징을 이용한 새로운 치료법들이 시도되고 있다. 이에 본고에서는 최근 진행성 췌장암의 항암 치료의 연구 동향에 대해 알아보고자 한다. Pancreatic cancer is still one of the most devastating cancers with less than 5% of 5-year survival even though the advances in modern medicine. Considering effective screening strategies and vaccinations has been improving clinical outcomes in other gastrointestinal malignancies, there is not yet effective tools for pancreatic cancer in earlier stage. Thus, about 80% of patients of pancreatic cancer are diagnosed as unsuitable for curative resection. Furthermore, recent experimental data suggest metastasis of pancreatic cancer can be developed in remarkably earlier stage during carcinogenesis. Based on these findings, systemic chemotherapy is the main therapeutic option for treating pancreatic cancer. However, the outcome of systemic chemotherapy is still disappointing even though recent data with FOLFIRINOX and nab-paclitaxel showed relatively promising. With advances in molecular technologies including next generation sequencing, the therapeutic paradigm for handling malignancies has been rapidly changing. The new wave of tailored or precision medicine leads to develop several novel therapeutic options like immune check point inhibitor or novel adoptive cell therapy. Herein, we will discuss the current status and perspectives of targeted therapy for pancreatic cancer.
친환경 고전압 전력기기 개발을 위한 GN₂의 절연특성 분석
방승민(Seungmin Bang),이온유(Onyou Lee),김준일(Junil Kim),강종오(Jong O Kang),이홍석(Hongseok Lee),고태국(Taekuk Ko),강형구(Hyoungku Kang) 대한전기학회 2014 전기학회논문지 P Vol.63 No.4
The environmental pollution caused by green-house gases such as GN₂ has been becoming the main issue of industrial society. As a part of these efforts, 180 countries signed the Kyoto Protocol in 1997 to cut back on their green-house gas emissions [1]. Therefore, a study on the dielectric characteristics of the GN₂ is important for designing a eco-friendly high voltage apparatuses. In this paper, to develop an electrically reliable, stable, and eco-friendly high voltage apparatus, the breakdown voltage and partial discharge inception voltage characteristics in GN₂ considering utilization factors are studied for the establishment of insulation design criteria of an high voltage apparatus. Dielectric experiments are performed by using several kinds of sphere-plane electrode systems made of stainless steel. Also, the dielectric characteristics of the GN₂ are analyzed by using a Finite Elements Method ( FEM ) according to various field utilization factors. The results are expected to be applicable to designing the high voltage apparatuses using GN₂ as an insulation gas.
항암화학요법과 수술을 통해 완전 관해를 획득한 진행성 십이지장 유두암 증례
윤해룡,정문재,방승민,박승우,송시영,Hae Ryong Yun,Moon Jae Chung,Seungmin Bang,Seung Woo Park,Si Young Song 대한소화기암연구학회 2014 Journal of digestive cancer reports Vol.2 No.2
Ampulla of Vater (AOV) cancer is rare malignant tumor which arises within the vicinity of the AOV. Metastatic AOV adenocarcinoma has poor prognosis, with an overall survival rate at 2 years ranging from 5 to 10%. The Surveillance, Epidemiology and End Results Program of the National Cancer Institute indicated that lymph node metastasis was present in as many as half of patients which were associated with poor prognosis and liver was the second most common site of distant metastasis in AOV cancer. In this case report, we describe a case of complete resolution of AOV cancer, which was already spread to retroperitoneal lymph node and liver. The patient underwent gemcitabine plus cisplatin chemotherapy for palliative aim. After 12 month of chemotherapy, image study showed partial remission, so intraoperative radiofrequency ablation therapy and pylorus preserving pancreaticoduodenectomy was done. AOV cancer was completely resected and the patient was followed up without recurrence for 7 months.